What does endotyping mean for treatment in chronic obstructive pulmonary disease?

[1]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[2]  Lisa Rosenbaum,et al.  Bridging the Data-Sharing Divide - Seeing the Devil in the Details, Not the Other Camp. , 2017, The New England journal of medicine.

[3]  M. Obeidat,et al.  Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease , 2017, Respiratory Research.

[4]  C. Manichanh,et al.  The microbiome in respiratory medicine: current challenges and future perspectives , 2017, European Respiratory Journal.

[5]  Meilan K. Han,et al.  Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity? , 2017, American journal of respiratory and critical care medicine.

[6]  A. Bush.  Lung Development and Aging. , 2016, Annals of the American Thoracic Society.

[7]  A. Agustí,et al.  Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine. , 2016, Annals of the American Thoracic Society.

[8]  Jesper Tegnér,et al.  From comorbidities of chronic obstructive pulmonary disease to identification of shared molecular mechanisms by data integration , 2016, BMC Bioinformatics.

[9]  Ivana V. Yang,et al.  Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. , 2016, American journal of respiratory and critical care medicine.

[10]  F. Martinez.  Early-Life Origins of Chronic Obstructive Pulmonary Disease. , 2016, The New England journal of medicine.

[11]  R. Rodríguez-Roisín,et al.  Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. , 2016, American journal of respiratory and critical care medicine.

[12]  L. Fabbri.  Smoking, Not COPD, as the Disease. , 2016, The New England journal of medicine.

[13]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[14]  A. Agustí,et al.  Biomarkers, the control panel and personalized COPD medicine , 2016, Respirology.

[15]  B. Celli,et al.  B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[16]  Ferran Sanz,et al.  Molecular and clinical diseasome of comorbidities in exacerbated COPD patients , 2015, European Respiratory Journal.

[17]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[18]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[19]  D. Longo,et al.  Precision medicine--personalized, problematic, and promising. , 2015, The New England journal of medicine.

[20]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[21]  A. Barabasi,et al.  A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. , 2015, Human molecular genetics.

[22]  A. Agustí,et al.  Drug development for airway diseases: looking forward , 2015, Nature Reviews Drug Discovery.

[23]  F. Martinez,et al.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management , 2015, The Lancet.

[24]  N. Schork.  Personalized medicine: Time for one-person trials , 2015, Nature.

[25]  Albert-László Barabási,et al.  A DIseAse MOdule Detection (DIAMOnD) Algorithm Derived from a Systematic Analysis of Connectivity Patterns of Disease Proteins in the Human Interactome , 2015, PLoS Comput. Biol..

[26]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[27]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[28]  C. Auffray,et al.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. , 2015, American journal of respiratory and critical care medicine.

[29]  Martin Hofmann-Apitius,et al.  Towards the taxonomy of human disease , 2015, Nature Reviews Drug Discovery.

[30]  Weiliang Qiu,et al.  Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods , 2015, BMC Medical Genomics.

[31]  E. Bleecker,et al.  Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. , 2014, The Lancet. Respiratory medicine.

[32]  Frederick B. Marcus,et al.  A systems medicine clinical platform for understanding and managing non- communicable diseases. , 2014, Current pharmaceutical design.

[33]  Craig E Wheelock,et al.  Network analysis in the investigation of chronic respiratory diseases. From basics to application. , 2014, American journal of respiratory and critical care medicine.

[34]  Pablo Villoslada,et al.  Modules, networks and systems medicine for understanding disease and aiding diagnosis , 2014, Genome Medicine.

[35]  J. Roca,et al.  Network medicine analysis of COPD multimorbidities , 2014, Respiratory Research.

[36]  Tudor I. Oprea,et al.  Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients , 2014, Nature Communications.

[37]  Meilan K. Han,et al.  Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. , 2014, American journal of respiratory and critical care medicine.

[38]  Martine Vrijheid,et al.  The exposome: a new paradigm to study the impact of environment on health , 2014, Thorax.

[39]  A. Agustí,et al.  Systemic Inflammatory Response to Smoking in Chronic Obstructive Pulmonary Disease: Evidence of a Gender Effect , 2014, PloS one.

[40]  A. Agustí.  The path to personalised medicine in COPD , 2014, Thorax.

[41]  Albert-László Barabási,et al.  A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease , 2014, BMC Systems Biology.

[42]  Meilan K. Han,et al.  Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial , 2013, European Respiratory Journal.

[43]  A. Agustí,et al.  Immune response in chronic obstructive pulmonary disease , 2013, Expert review of clinical immunology.

[44]  I. Pavord,et al.  Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? , 2013, Thorax.

[45]  B. Beghé,et al.  Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD , 2013, European Respiratory Journal.

[46]  L. Wood,et al.  Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? , 2013, Thorax.

[47]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[48]  Alvar Agusti,et al.  The COPD control panel: towards personalised medicine in COPD , 2012, Thorax.

[49]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[50]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[51]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[52]  C. Wild,et al.  The exposome: from concept to utility. , 2012, International journal of epidemiology.

[53]  H. Kitano,et al.  Software for systems biology: from tools to integrated platforms , 2011, Nature Reviews Genetics.

[54]  A. Barabasi,et al.  Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[55]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[56]  I. Kola,et al.  A call to reform the taxonomy of human disease , 2011, Nature Reviews Drug Discovery.

[57]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[58]  B. Celli,et al.  Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. , 2011, American journal of respiratory and critical care medicine.

[59]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[60]  I. Pavord,et al.  Acute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers , 2011 .

[61]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[62]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[63]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[64]  Alvar Agusti,et al.  Immunologic aspects of chronic obstructive pulmonary disease. , 2009, The New England journal of medicine.

[65]  S. Salvi,et al.  Chronic obstructive pulmonary disease in non-smokers , 2009, The Lancet.

[66]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[67]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[68]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[69]  F. Sciurba,et al.  Autoantibodies in patients with chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[70]  K. Rabe,et al.  From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.

[71]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[72]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[73]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[74]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[75]  H. Coxson,et al.  Antielastin autoimmunity in tobacco smoking–induced emphysema , 2007, Nature Medicine.

[76]  S. Biswal,et al.  Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. , 2006, Proceedings of the American Thoracic Society.

[77]  P. Jones,et al.  Outcomes and markers in the assessment of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[78]  I. Adcock,et al.  Epigenetics and airways disease , 2006, Respiratory research.

[79]  I. Pavord,et al.  Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[80]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[81]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[82]  H. Kitano,et al.  Computational systems biology , 2002, Nature.

[83]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[84]  Hiroaki Kitano,et al.  Foundations of systems biology , 2001 .

[85]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[86]  Farid Neema,et al.  Data sharing , 1998 .

[87]  P. J. Barnes,et al.  Increased nitric oxide in exhaled air of asthmatic patients , 1994, The Lancet.

[88]  J. Scadding,et al.  Health and disease: what can medicine do for philosophy? , 1988, Journal of medical ethics.

[89]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[90]  C. Laurell.  Is emphysema in alpha 1 -antitrypsin deficiency a result of autodigestion? , 1971, Scandinavian journal of clinical and laboratory investigation.

[91]  G. Turino,et al.  Serum Elastase Inhibitor Deficiency and αl-Antitrypsin Deficiency in Patients with Obstructive Emphysema , 1969, Science.

[92]  C. Laurell,et al.  Obstructive Lung Disease and Trypsin Inhibitors in α1-Antitrypsin Deficiency , 1967 .